MedTrace Logo

Angiogenic Switch in Patients With Colorectal Cancer

NCT02075086 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2015-03-17

No results posted yet for this study

Summary

A group of colorectal cancer (CRC) patients treated with chemotherapy and Bevacizumab (Bev) maintain the same sensitivity after progression to maintenance treatment because they remain dependent on VEGF angiogenic mediator, while other patients in whom there is an angiogenic switch (AS) become dependent on other angiogenic cytokines and become resistant to Bev chemotherapy combinations .

Conditions

Interventions

DRUG

Xelox or Xeliri Bevacizumab

Chemotherapy treatment

Sponsors & Collaborators

  • Grupo Hospital de Madrid

    lead OTHER

Principal Investigators

  • Antonio Cubillo, MD PhaD · Grupo Hospital de Madrid

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02075086 on ClinicalTrials.gov